Obesity-associated asthma in childhood

Maria Mangova1,2*, Tobias Lipek1,2*, Maike vom Hove1,2, Antje Körner1, Wieland Kiess1,2, Regina Treudler2,3, and Freerk Prenzel1,2

1University of Leipzig Medical Center, Department for Pediatrics, 2LICA – Leipzig Interdisciplinary Center for Allergy (Comprehensive Allergy Center), and 3University of Leipzig Medical Center, Department of Dermatology, Venereology and Allergy, Leipzig, Germany

Abstract. Obesity and bronchial asthma are very common diseases in children and adolescents, associated with a considerable burden of disease, reduced quality of life and comorbidities. Obesity is a significant risk factor for bronchial asthma. On the one hand, obesity leads to changes in the mechanics and function of the lungs and chest. On the other hand, obesity-associated inflammatory processes with increased production of leptin and cytokines may trigger bronchial inflammation with the appearance of asthmatic symptoms. The diseases are also linked by genetic factors. Physical activity and weight reduction have a significant benefit. Pharmacotherapy must be based on the pattern of inflammation. This article summarizes the current state of the literature on the association of asthma and obesity and presents current and possible future treatment options.

Introduction

Asthma and obesity are two of the most common diseases in pediatrics, the prevalence of which has increased in parallel over the last decades and has recently reached a plateau [1, 2, 3]. Bronchial asthma is pathophysiological defined as an inflammatory respiratory disease with symptoms that vary in time and intensity, such as shortness of breath, wheezing, chest tightness and coughing, and bronchial hyperresponsiveness. There is a complex interaction of endogenous and genetic factors and exogenous stimuli of physical, chemical, pharmacological, and immunological nature resulting in mucus hypersecretion, bronchospasm, mucosal edema, and remodeling [1].

Obese children often have dyspnea and other respiratory problems, but these are not always due to asthma. Overweight and obesity in children is a clear risk factor for bronchial asthma, especially in girls [1, 4]. When obese children develop asthma, they have a more severe disease phenotype associated with a higher burden of disease, reduced quality of life, greater frequency of exacerbations and hospitalization, and a suboptimal response to commonly used asthma medicines [5, 6, 7, 8]. The mechanisms underlying obesity-associated asthma are not yet fully understood. However, there is increasing evidence that asthma is associated with systemic inflammation of fatty tissue [7, 9, 10]. This paper provides an up-to-date literature review on the association of childhood obesity and asthma and presents current and possible future therapeutic strategies.

Units of measurement for obesity and influencing factors on bronchial asthma

Obesity is present when the proportion of body fat in the total body mass is pathologically increased. Since the fat percentage of the body can only be determined exactly with elaborate methods, the use of the easily measurable parameters height and body weight as well as the body mass index (BMI = body weight/height\(^2\) (kg/m\(^2\)) derived from these parameters for estimating the body fat percentage in adults has become established worldwide. In accordance with the specifications of the European Childhood Obesity Group, the Working Group on Obesity in Childhood and Adolescence recommends the use of the 90th or 97th age- and gender-specific BMI percentile as a limit value for defining overweight or obesity. Extreme obesity is defined as a BMI > 99.5th percentile [11].
Obesity-associated asthma in childhood

Many prospective studies on obesity and asthma have primarily used the BMI as an indicator of obesity. Other indicators have been measures of fat distribution, such as skin-fold thickness, waist and hip circumference, and body composition [12, 13, 14].

The association of obesity and asthma is modified by many influencing factors. In a German cohort study, evidence was found that obesity is only independently associated with asthma among children with an atopic disposition [13]. Gender also seems to play a role: In a large prospective longitudinal study in children, Wadden et al. [15] showed an additional effect of the female sex on increasing BMI and persistent asthma. The potential anti-inflammatory hormone effect of testosterone and the pro-inflammatory effect of estrogen are discussed, as it has been shown that asthma occurs more frequently in early childhood in boys and postpubertal in girls [16].

### Relationship between obesity and lung function

Obesity causes significant changes in the mechanics of the lungs and thorax with reduction in pulmonary compliance. This alters the breathing pattern and probably contributes to respiratory symptoms such as wheezing, dyspnea, and orthopnea. The increased intra-abdominal and pleural pressures lead to a reduction in expiratory reserve volume (ERV) and functional residual capacity (FRC) (Figure 1) [8].

Studies have shown that children with obesity tend to have large lungs, but their airways are normally sized. This mismatch between lung tissue growth and airway caliber is called “airway dysanapsis” [17]. As a result, obese children have normal forced expiratory volume in one second (FEV1) and normal expiratory flow with increased forced vital capacity (FVC) compared to normal-weight children. Accordingly, the FEV1/FVC ratio (Tiffeneau index) used for the diagnosis of asthma is reduced [17, 18, 19, 20, 21, 22]. Since an important cause of the symptoms could therefore be mechanical rather than inflammatory, it is not surprising that a reduced response to inhaled corticosteroids is often observed in obese children with respiratory dysanapsis [18, 23].

In other studies, however, no clear correlation has been found between BMI and lung function parameters in children with asthma [24]. The concept of dysanapsis requires further prospective evaluation and does not appear to be sufficient on its own to describe the association between asthma and obesity.

### Inflammation pattern in obesity-associated asthma

Fatty tissue has been in the focus of science for quite some time because of the many negative health effects of overweight. With regard to asthma, the pro-inflammatory effects of adipose tissue and the potential role of this inflammation as an effect modifier on bronchial asthma have been investigated in several studies (Figures 1 and 2) [25, 26, 27, 28]. In normal-weight people, adipose tissue typically secretes small amounts of pro-inflammatory cytokines such as IL-
6, IL-8, tumor necrosis factor-α (TNF-α) and adipokines such as leptin, and produces large amounts of the anti-inflammatory adipokine adiponectin. In the obese state, fatty tissue hypertrophies and is infiltrated by pro-inflammatory macrophages. These activated macrophages and hypertrophied adipocytes produce increased pro-inflammatory cytokines and leptin and decreased adiponectin. This metabolic inflammation is believed to cause the systemic complications of obesity such as type 2 diabetes, hepatic steatosis, and metabolic syndrome [9, 15, 29, 30].

This has led to the assumption that the same mechanism may be involved in bronchial inflammation in asthma. This is supported by the fact that systemic inflammation is more pronounced in patients with obesity-associated asthma than in obese patients without asthma [31]. Of central importance is the adipokine leptin, which plays an important role in embryonic and fetal development and in controlling body fat stores by regulating eating habits, metabolism, the autonomic nervous system, and the body’s energy balance [32]. However, leptin is also involved in the regulation of the respiratory drive, surfactant production, and lung development in newborns [33, 34, 35, 36]. Given these functions, leptin may well be involved in the pathogenesis of respiratory diseases.

Levels of leptin are higher in obese children and adults than in non-obese ones [30, 37]. However, the expression of leptin is significantly increased in obese children and adults with asthma compared to obese patients without asthma [9, 26]. Children with uncontrolled asthma had higher leptin levels than those with controlled asthma (Figure 2) [26].

In addition, Zheng et al. [27] suggested that leptin acts as a key risk factor for the development of allergic asthma in obese individuals through the induction of the unfolded protein response factor XBP1s, which stimulates pro-allergic lymphocyte survival and cytokine production. This would build a bridge to the above-mentioned finding that obesity is a risk factor especially in connection with atopy [13].

The macrophages of fatty tissue are significantly elevated and mediate both local and systemic inflammation, leading to the recruitment and activation of type 1 T-helper cells [9, 38, 39, 40]. Their activation enhances the immune response by producing additional pro-inflammatory cytokines and inflammatory markers such as TNF-α, IL-8 and IL-6, highly sensitive C-reactive protein (hs-CRP) and monocyte chemoattractive protein-1 (MCP-1) [41, 42, 43, 44]. The latter causes an activation of monocytes and their transformation into macrophages [10].
The influence of this systemic inflammation on the bronchial system has not yet been fully clarified. However, it is known that TNF-α is elevated in uncontrolled, severe asthma [45]. The above-mentioned pro-inflammatory cytokines can influence lung function by activating vascular endothelial cells, respiratory fibroblasts, smooth muscle cells, or respiratory epithelial cells [46]. In addition, IL-6 affects the differentiation of naive T cells into Th17 cells and may indirectly affect lung function through the action of IL-17 [47, 48]. Furthermore, TNF-α is involved in the recruitment of neutrophils and eosinophils and the activation of T cells in the airways. Thus, there are connections between type 1 (TH2-low) and type 2 (TH2-high) inflammation [48, 49, 50]. This and the activation of congenital type 2 lymphoid cells (ILC2s) could explain why elevated T2 cytokines such as IL-4 and IL-5 are found in asthma in parallel to an increase in TNF-α [26, 44].

IL-4 stimulates B-cell and T-cell proliferation and the differentiation of CD4+ T cells into Th2 cells. IL-4 also plays a central role in the regulation of IgE synthesis and induces the expression of the low-affinity IgE receptor on macrophages. IL-5 is an activator for eosinophils and is therefore considered a central cytokine in allergen- and parasite-mediated eosinophilic reactions. IL-5 stimulates B-cell growth and increases immunoglobulin secretion [49]. Nevertheless, no increase in fractional exhaled nitric oxide (FENO) as an eosinophilic inflammation marker has been shown in obese children [51].

In the literature, obesity-associated asthma is described on the one hand as being associated with neutrophilic or paucigranulocytic airway inflammation, and thus T2-low [52]. On the other hand, increased IL-5 and submucosal eosinophilia have been found in the sputum of obese patients with severe asthma [53].

In another study, no significant difference was found histologically in lung biopsies of adults with mild to moderate asthma compared to a control group of obese patients without asthma [54].

It is possible that specific inflammatory mechanisms such as the CDC42 pathway also play a role in obesity asthma [10].

In summary, obesity-associated asthma is characterized by a systemic inflammation of adipose tissue with cytokines and markers that initially correspond to a non-eosinophilic T2-low inflammation. However, there appears to be an overlap with T2-high asthma, which may be clinically significant. It may also be necessary to distinguish between obesity-exacerbated asthma and obesity-induced asthma [52].

Further elucidation of these pathogenetic mechanisms is of great importance for the development of targeted therapeutic strategies.

**Genetics and epigenetics of obesity and asthma**

The different efficacy of steroids in the treatment of asthma in children with and without obesity is a clinically significant finding, which led to the investigation of molecular-genetic causes. At birth it is not yet completely decided whether a child becomes overweight. Therefore, postnatal epigenetic changes in particular are considered. Using single nucleotide polymorphisms (SNP), it can be said that the epigenetic footprint of immune cells of obese children with bronchial asthma differs from that of obese children without asthma and normal-weight children with asthma [31]. Granell et al. [55] confirmed a positive association between BMI and asthma in middle childhood in their population-based birth cohort study and found strong evidence that this association is due to a causal effect of BMI on asthma using randomization analyses based on 32 BMI-associated SNPs.

Some genes have been identified as associated with asthma and obesity [56]. This includes on chromosome 5q31-32 the genes ADRB2, which encodes the adrenergic β2 receptor, and NR3C1, which codes for the glucocorticoid receptor. Interestingly, these are both genes that are important in the context of therapy. Furthermore, on chromosome 6p21.3 this concerns the TNF-α gene complex and on chromosome 11q13 the genes UCP2, UCP3, and the low-affinity immunoglobulin E-receptor gene.

Future studies will hopefully provide further insights into the genetic influence of the association between obesity and asthma.
Comorbidities and quality of life in children with asthma and obesity

Asthma is associated with metabolic dysregulation including insulin resistance, dyslipidemia, and metabolic syndrome. The prevalence of metabolic dysregulation such as insulin resistance and dyslipidemia, especially low levels of high-density lipoprotein (HDL), is higher in obese children with asthma than in normal-weight children with asthma [57, 58, 59]. Asthma and obesity also have some overlapping comorbidities such as psychosocial problems including depression and anxiety disorders, upper respiratory tract disorders, obstructive sleep apnea syndrome, dysfunctional respiratory symptoms, and gastroesophageal reflux [1, 60, 61, 62].

These overlapping comorbidities could be mutually reinforcing and must therefore be included in therapy. On the other hand, some comorbidities of obesity, such as obstructive sleep apnea and gastroesophageal reflux, may simulate asthma symptoms and lead to misinterpretation and the use of unnecessary anti-asthmatic medication that does not result in clinical improvement.

Many studies have concluded that the quality of life in children with asthma and obesity is significantly lower in the long term than in healthy subjects. Physical activity was the most severely restricted [24].

Treatment

Sport, diet, and socio-economic factors

Today’s sedentary lifestyle, with the use of social media, electronic devices, television, and video games, has reduced active time outdoors and is therefore associated with overweight and obesity in children [63]. If obesity is one of the causes of changes in lung mechanics and function, weight loss should be able to reverse these changes. Aerobic fitness and physical activity clearly play a role in treating childhood obesity and asthma [7, 64]. The number of studies on the effect of weight loss on childhood asthma associated with obesity is limited. However, a benefit has been shown in terms of lung function, asthma control and symptoms, the severity of exercise-induced bronchoconstriction, and quality of life [65, 66, 67, 68, 69, 70].

In adult patients who have undergone bariatric surgery, an improvement in airway hyperreactivity, in lung volume and function of the small airways as well as in the systemic inflammatory situation have been observed [71, 72, 73].

Pharmacotherapy

Children with obesity and asthma should be treated according to current guidelines, which include therapy with inhaled corticosteroids (ICS), especially if there is evidence of allergic disease [1, 7]. It should be noted, however, that a reduced response to medication and poorer disease control is observed in this patient group [74, 75, 76, 77, 78].

While a number of biologicals are already available for T2-high asthma [79, 80], the therapeutic options for obesity-associated asthma are unclear. In this phenotype, as outlined above, the pattern of inflammation has not yet been sufficiently characterized. TNF-α receptor blockers initially showed encouraging results, but these could not be confirmed [45, 81]. Therapy with an anti-TNF-α antibody did not show a favorable adverse event profile, and anti-IL-17 therapy did not result in an improvement [52, 82]. The macrolide azithromycin could reduce the rate of exacerbation in adult patients with non-eosinophilic asthma [52, 80]. Interestingly, a reduction in BMI was observed in asthma under anti-IL-5 therapy, which was associated with the role of eosinophils in the homeostasis of these cells in adipose tissue [83].

Future therapeutic options

Since insulin resistance and a metabolic syndrome lead to a worsening of bronchial asthma and lung function, therapy of these complications is also useful with regard to pulmonary disease [84, 85]. Initial data in adults have shown that metformin may also improve asthma exacerbations in patients with metabolic syndrome [86]. The role of anti-IL-5 therapy needs further evaluation [53, 83], and an anti-IL-1 antibody is still being investigated in clinical trials [52]. Antithymic stromal lymphopoietin (TSLP) ther-
apy, for example with tezepelumab, is also a possible approach [87].

Liraglutide can be used in the treatment of diabetes mellitus type 2 and severe obesity. In addition, improvements in bronchial asthma have been described in a mouse model [88].

Conclusion

The prevalence of asthma and obesity in children and adolescents has increased in many countries. Obese children have a higher risk of developing asthma than normal-weight children [89]. Obesity-associated asthma is associated with a higher burden of disease and associated reduced quality of life, reduced lung function and disease control, a higher incidence of exacerbations and hospitalization, and a suboptimal response to commonly used asthma medication [5, 6, 90]. As obesity can cause respiratory symptoms, there is a risk of overdiagnosis [1].

Obesity-associated asthma probably develops from a systemic inflammation originating in fatty tissue that is associated with an imbalance of leptin and adiponectin. Phenotypically, T2-low inflammation seems to be predominant, but overlaps with T2-high asthma are observed.

Asthma should always be diagnostically confirmed, whereas FEV1 and expiratory flow restriction should rather be used for the detection of pulmonary obstruction due to respiratory dysanapsis. Evidence of bronchial hyperresponsiveness may confirm asthma; a low FENO indicates T2-high asthma.

Also on the genetic level and in the case of other comorbidities, associations between obesity and asthma arise that may be therapeutically relevant.

Therapeutically, weight reduction and sports are important interventions with clear clinical benefits. Pharmacotherapy is performed according to guidelines including ICS, whereby a benefit must be verified and an uncritical use of high-dose ICS must be avoided.

Future research should clarify the pathomechanisms of obesity-associated asthma and help to better characterize this phenotype and sub-phenotypes. Based on this, new therapeutic approaches must be identified and reviewed. Primary prevention strategies and ways to implement lifestyle interventions must be developed.

Essential sentence

Obesity and asthma in children are associated by inflammatory and mechanical processes that must be taken into account in therapy.

Funding

No external funding.

Conflict of interest

The authors declare that there is no conflict of interest.

References

[1] Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available from: www.ginasthma.org. 2020.
[2] Prugger C, Keil U. [Development of obesity in Germany – prevalence, determinants and perspectives]. Dtsch Med Wochenschr. 2007; 132: 892-897. CrossRef PubMed
[3] Keß A, Spielau U, Beger C, Gausche R, Vogel M, Lipek T, Körner A, Pfäffle R, Kiess W. Further stabilization and even decrease in the prevalence rates of overweight and obesity in German children and adolescents from 2005 to 2015: a cross-sectional and trend analysis. Public Health Nutr. 2017; 20: 3075-3083. CrossRef PubMed
[4] Deng X, Ma J, Yuan Y, Zhang Z, Niu W. Association between overweight or obesity and the risk for childhood asthma and wheeze: An updated meta-analysis on 18 articles and 73 252 children. Pediatr Obes. 2019; 14: e12532. CrossRef PubMed
[5] McGarry ME, Castellanos E, Thakur N, Oh SS, Eng C, Davis A, Meade K, LeNoir MA, Avila PC, Farber HJ, Serebrisky D, Brigino-Buenaventura E, Rodriguez-Cintron W, Kumar R, Bibbins-Domingo K, Thyne SM, Sen S, Rodriguez-Santana JR, Borrell LN, Burchard EG. Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma. Chest. 2015; 147: 1591-1598. CrossRef PubMed
[6] Borrell LN, Nguyen EA, Roth LA, Oh SS, Tcheurekdjian H, Sen S, Davis A, Farber HJ, Avila PC, Brigino-Buenaventura E, LeNoir MA, Larmann F, Meade K, Serebrisky D, Rodriguez-Cintron W, Kumar R, Rodriguez-Santana JR, Thyne SM, Burchard EG. Childhood obesity and asthma control in the GALA II and SAGE II studies. Am J Respir Crit Care Med. 2013; 187: 697-702. CrossRef PubMed
[7] Lang JE. Obesity and childhood asthma. Curr Opin Pulm Med. 2019; 25: 34-43. CrossRef PubMed
[8] Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018; 141: 1169-1179. CrossRef PubMed
from a random population sample of school children examines the effects of body fat on ventilatory function in children and adolescents. Pediatr Pulmonol. 2020; 55: 809-817. CrossRef PubMed

[11] Wabitsch M, Moss A; federführend für die AGA. Evidenzbasierte (S3-) Leitlinie der Arbeitsgemeinschaft Adipositas im Kindes- und Jugendalter (AGA) der Deutschen Adipositas-Gesellschaft (DAG) und der Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ); Evidenzbasierte (S3-) Leitlinie der Arbeitsgemeinschaft Adipositas im Kindes- und Jugendalter (AGA) der Deutschen Adipositas-Gesellschaft (DAG) und der Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ). 2019.

[12] Menezes AMB, de Oliveira PD, Blumenberg C, Sanchez-Angarita E, Niño-Cruz GI, Zaberi I, Costa JC, Ricardo LIC, Martins RC, Wehrmeister FC. Longitudinal association of adiposity with wheezing and atopy at 22 years: the 1993 Birth Cohort, Pelotas, Brazil. J Asthma Allergy. 2018; 11: 283-291. CrossRef PubMed

[13] Gramss M, Li pek T, Vogel M, Remmler J, Hienisch A, Jurkatat A, Genuneit J, Körner A, Kiess W. Overweight proxies are associated with atopic asthma: a matched case-control study. Horm Res Paediatri. 2019; 91: 380-390. CrossRef PubMed

[14] Chen Y-C, Tu Y-K, Huang K-C, Chen P-C, Chu D-C, Lee Y-L. Pathway from central obesity to childhood asthma. Physical fitness and sedentary time are leading factors. Am J Respir Crit Care Med. 2014; 189: 1194-1203. CrossRef PubMed

[15] Wadden D, Allwood Newhook LA, Twells L, Farrell J, Guo Z. Sex-specific association between childhood BMI trajectories and asthma phenotypes. Int. J. Pediatr. 2018; 2018: 9057435. CrossRef PubMed

[16] Keller T, Hohmann C, Staudt M, Wyjs AH, Gehring U, Melén E, Almqvist C, Law S, Eller E, Wühn A, Christiansen ES, von Berg A, Heinrich J, Lehmann I, Maier D, Postma DS, Antó JM, Bossuet J, Keil T, Roll S. The sex-shift in single disease and multimorbid asthma and rhinitis during puberty – a study by McDAll. Allergy. 2018; 73: 602-614. CrossRef PubMed

[17] Forno E, Weiner DJ, Mullen J, Savicki G, Kurland G, Han YY, Cloutier MM, Canino G, Weiss ST, Litonjua AA, Celedón JC. Obesity and airway dysanapsis in children with and without asthma. Am J Respir Crit Care Med. 2017; 195: 314-323, 10.1164/rcmm.2016-051039OCrossRef PubMed

[18] Forno E, Han Y-Y, Mullen J, Celedón JC. Overweight, obesity, and lung function in children and adults – A meta-analysis. J Allergy Clin Immunol Pract. 2018; 6: 570-581.e10. CrossRef PubMed

[19] Lazarus R, Colditz G, Berkley CS, Speizer FE. Effects of body fat on ventilatory function in children and adolescents: cross-sectional findings from a random population sample of school children. Pediatr Pulmonol. 1997; 24: 187-194. CrossRef PubMed

[20] Rastogi D, Canfield SM, Andrade A, Issai CR, Hall CB, Rubinstein A, Arens R. Obesity-associated asthma in children: a distinct entity. Chest. 2012; 141: 895-905. CrossRef PubMed

[21] Cha Y-T, Chen W-Y, Wang T-N, Tseng H-I, Wu J-R, Ko Y-C. Extreme BMI predicts higher asthma prevalence and is associated with lung function impairment in school-aged children. Pediatr Pulmonol. 2009; 44: 472-479. CrossRef PubMed

[22] Spathopoulos D, Paraskakis E, Trypsialis G, Tsaklidas A, Arvantidou V, Emporiodoulos B, Bouras D, Chatzimichael A. The effect of obesity on pulmonary lung function of school-aged children in Greece. Pediatr Pulmonol. 2009; 44: 273-280. CrossRef PubMed

[23] Davidson WJ, Mackenzie-Rife KA, Witmans MB, Montgomery MD, Ball GDC, Eghogah S, Eves ND. Obesity negatively impacts lung function in children and adolescents. Pediatr Pulmonol. 2014; 49: 1003-1010. CrossRef PubMed

[24] Habib SS, Alshahabi M, Alzahrani A, Alsaud A, Alzahrani K, Alawatasi S, Alhendas K, Al Saadi M, Bashir S. Relationship of asthma control test scores with pulmonary function tests, quality of life and adiposity in asthmatic children. Eur Rev Med Pharmacol Sci. 2020; 24: 345-351. CrossRef PubMed

[25] Garcia-Rio F, Alvarez-Puebla MJ, Esteban-Gorrojo I, Barranco P. Obaguel JM. Obesity and asthma: Key clinical questions. J Invest Allergol Clin Immunol. 2019; 29: 262-271. CrossRef PubMed

[26] Al-Ayed M, Alshaybaky K, Alshehi D, Jamaan A, Nasser I, Aalaami H, Alaseeri W, Mahfouz AA, Ali Alseardi S, Asaad AM, Ali Magaoub A, Qureshi MA, Shalayel MH. Obesity and childhood asthma in male schoolchildren in Saudi Arabia: Is there a role for leptin, interleukin-4, interleukin-5, and interleukin-21? Ann Saudi Med. 2019; 39: 295-301. CrossRef PubMed

[27] Zheng H, Wu D, Wu X, Zhang X, Zhou Q, Luo Y, Yang X, Chock CJ, Liu M, Yang X0. Leptin promotes allergic airway inflammation through targeting the unfolded protein response pathway. Sci Rep. 2018; 8: 8905. CrossRef PubMed

[28] Vijayananthi N, Greally JM, Rastogi D. Pediatric obesity-related asthma: The role of metabolic dysregulation. Pediatrics. 2016; 137: e20150812 CrossRef PubMed

[29] Lameng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011; 121: 2111-2117. CrossRef PubMed

[30] Izquierdo AG, Crujeiras AB, Casanueva FF, Carreirac M. Leptin, obesity, and leptin resistance: Where are we 25 years later? Nutrients. 2019; 11: E2704. CrossRef PubMed

[31] Rastogi D, Holguin F. Metabolic dysregulation, systemic inflammation, and pediatric obesity-related asthma. Ann Am Thorac Soc. 2017; 14 (Supplement_5): S363-S367. CrossRef PubMed

[32] Kiess W, Petzold S, Töpfer M, Garten A, Blüher S, Kapellen T, Körner A, Kratzsch J. Adipocytes and adipose tissue. Best Pract Res Clin Endocrinol Metab. 2008; 22: 135-153. CrossRef PubMed

[33] Polotsky VY, Smaldone MC, Scharf MT, Li J, Tankereley CG, Smith PL, Schwartz AR, O'Donnell CP. Impact of disrupted leptin pathways on ventilatory control. J Appl Physiol (1985). 2004; 96: 991-998. CrossRef PubMed

[34] Bassi M, Faruwa WI, Menani JV, Colombari DSA, da Carmo JM, da Silva AA, Hall JE, Moreira TS,
Obesity-associated asthma in childhood

Wenker IC, Malkey DK, Colombari E. Leptin into the ventrolateral medulla facilitates chemorespiratory response in leptin-deficient (ob/ob) mice. Acta Physiol (Oxf). 2014; 211: 240-248. CrossRef PubMed

Tonday JS, Powell FL, Farmer CG, Orgeig S, Nielsen HC, Hall AJ. Leptin integrates vertebrate evolution: from oxygen to the blood-gas barrier. Respir Physiol Neurobiol. 2010; 173 (Suppl): S37-S42. CrossRef PubMed

De Blasio MJ, Boije M, Kempster SL, Smith GCS, Charnock-Jones DS, Denyer A, Hughes A, Wooding FBP, Blache D, Fowden AL, Forhead AJ. Leptin Matures aspects of lung structure and function in the ovine fetus. Endocrinology. 2016; 157: 395-404. CrossRef PubMed

Verrotti A, Baschieri F, Morgese G, Chiarelli F. Leptin levels in non-obese and obese children and young adults with type 1 diabetes mellitus. Eur J Endocrinol. 1998; 139: 49-53. CrossRef PubMed

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-1808. CrossRef PubMed

Periyali HA, Wood LG, Wright TA, Karibhaloo C, Starkey MR, Miu AS, Baines KJ, Hansbro PM, Gibson PG. Obese asthmatics are characterized by altered adipose tissue macrophage activation. Clin Exp Allergy. 2018; 48: 641-649. 10.1111/cea.13109 CrossRef PubMed

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005; 115: 911-919, quiz 920. CrossRef PubMed

Bullo M, Garcia-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res. 2003; 11: 525-531. CrossRef PubMed

Bastard JP, Jardel C, Bruckert E, Blouy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000; 85: 3338-3342. CrossRef PubMed

Roth CL, Krazt M, Ralston MM, Reinehr T. Changes in adipose-derived inflammatory cytokines and chemokines after successful lifestyle intervention in obese children. Metabolism. 2011; 60: 445-452. CrossRef PubMed

Bradding P, Roberts JA, Britten KM, Montefort S, Djukanicov R, Mueller R, Heusser CH, Howarth PH, Holgate ST. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994; 10: 471-480. CrossRef PubMed

Berry MA, Hargaden B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006; 354: 697-708. CrossRef PubMed

Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012; 8: 1281-1290. CrossRef PubMed

Yung XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007; 282: 9358-9363. CrossRef PubMed

Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol. 2008; 121: 5-10, quiz 11-12. CrossRef PubMed

Fahy JV. Type 2 inflammation in asthma – present in most, absent in many. Nat Rev Immunol. 2015; 15: 57-65. CrossRef PubMed

Albrecht M, Dittrich A-M. Cytokines in sensitization to aerosolergens. Allergol Select. 2018; 2: 94-100. An erratum can be found at: https://www.nature.com/articles/ni3807 CrossRef PubMed

Umano GR, Pistone C, Tondina E, Moiraghi A, Laurretta D, Miraglia Del Giudice E, Brambilla I. Pediatric obesity and the immune system. Front Pediatr. 2019; 7: 487. CrossRef PubMed

Carr TF, Zeki AA, Kraft M. Eosinophilic and non-eosinophilic asthma. Am J Respir Crit Care Med. 2018; 197: 697-708. An erratum can be found at: https://www.nature.com/articles/nri3807 Clearinghouse/obesity-update-full-guide

van Huisstede A, Redolphus A, van Schadewijk A, Cabezas MC, Mannsperger GH, Taube C, Hemsstra PS, Braunstuhl G-J. Bronchial and systemic inflammation in morbidly obese subjects with asthma: a biopsy study. Am J Respir Crit Care Med. 2014; 190: 951-954. CrossRef PubMed

Granell R, Henderson AJ, Evans DM, Smith GD, Ness AR, Lewis S, Palmer TM, Sterne JAC. Effects of BMI, fat mass, and lean mass on asthma in childhood: a Mendelian randomization study. PLoS Med. 2014; 11: e1001669. CrossRef PubMed

Ali Z, Ulrik CS. Obesity and asthma: a coincidence or a causal relationship? A systematic review. Respir Med. 2013; 107: 1287-1300. CrossRef PubMed

Al-Shawwa BA, Al-Huniti NH, DeMatia L, Gershon W. Asthma and insulin resistance in morbidly obese children and adolescents. J Asthma. 2007; 44: 469-473. CrossRef PubMed

Cotrell L, Neal WA, Ice C, Perez MK, Piedmonte G. Metabolic abnormalities in children with asthma. Am J Respir Crit Care Med. 2011; 183: 441-448. CrossRef PubMed

Al-Shawwa B, Al-Huniti N, Titus G, Abu-Hasan M. Hypercholesterolemia is a potential risk factor for asthma. J Asthma. 2006; 43: 231-233. CrossRef PubMed

Bush A. Management of asthma in children. Minerva Pediatr. 2018; 70: 444-457. CrossRef PubMed

National Clinical Guideline Centre. Obesity – Identification, assessment and management of overweight and obesity in children, young people and adults. 2014. https://www.nice.org.uk/guidance/cg189/evidence/obesity-update-full-guide-line-pdf-193342429 (accessed 25 June 2020).
bolic syndrome in children. J Pediatr Endocrinol Metab. 2020; 33: 821-833. CrossRef PubMed

[63] Ghavamzadeh S, Khalkhali HR, Alizadeh M. TV viewing, independent of physical activity and obesogenic foods, increases overweight and obesity in adolescents. J Health Popul Nutr. 2013; 31: 334-342. CrossRef PubMed

[64] Lu KD, Manoskon K, Radom-Aizik S, Cooper DM, Galano SP. Obesity, asthma, and exercise in child and adolescent health. Pediatr Exerc Sci. 2016; 28: 264-274. CrossRef PubMed

[65] Dixon B, Peña M-M, Taveras EM. Life course approach to racial/ethnic disparities in childhood obesity. Adv Nutr. 2012; 3: 73-82. CrossRef PubMed

[66] Jensen ME, Gibson PG, Collins CE, Hilton JM, Wood LG. Diet-induced weight loss in obese children with asthma: a randomized controlled trial. Clin Exp Allergy. 2013; 43: 775-784. CrossRef PubMed

[67] van Leeuwen JC, Hoogstrate M, Duivenman EJ, Thio BJ. Effects of dietary induced weight loss on exercise-induced bronchoconstriction in overweight and obese children. Pediatr Pulmonol. 2014; 49: 1155-1161. CrossRef PubMed

[68] da Silva PL, de Mello MT, Cheik NC, Sanches PL, Correia FA, de Piana A, Corgosinho FC, Campos RMS, do Nascimento LF, Oyama LM, Teck L, Tufik S, Dámaso AR. Interdisciplinary therapy improves biomarkers profile and lung function in asthmatic obese adolescents. Pediatr Pulmonol. 2012; 47: 8-17. CrossRef PubMed

[69] Luna-Pech JA, Torres-Mendoza BM, Luna-Pech JA, Garcia-Cobas CY, Navarrete-Navarro S, Elizalde-Lozano AM. Normocaloric diet improves asthma-related quality of life in obese pubertal adolescents. Int Arch Allergy Immunol. 2014; 163: 252-258. CrossRef PubMed

[70] Willeboorde M, van de Kant KDG, Tan FES, Mulkins S, Schellings J, Crijns Y, van der Ploeg L, van Schayck CP, Dompeling E. Correction: A multifactorial weight reduction programme for children with overweight and asthma: A randomized controlled trial. PLoS One. 2017; 12: e0181130. CrossRef PubMed

[71] van Huisstede A, Rudolphus A, Castro Cabezas M, Biter LU, van de Geijn G-J, Taube C, Hiemstra PS, Braunstahl G-J, van Schadewijk A. Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax. 2015; 70: 659-667. CrossRef PubMed

[72] Dixon AE, Praley RE, Forgione PM, Kaminsky DA, Whittaker-Leclair LA, Grifffes LA, Garudathri J, Raymond D, Poynter ME, Bunn JY, Irvin CG. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011; 128: 509-515.e1-2. CrossRef PubMed

[73] Boulet L-P, Turcotte H, Martin J, Poirier P. Effect of bariatric surgery on airway response and lung function in obese subjects with asthma. Respir Med. 2012; 106: 651-660. CrossRef PubMed

[74] Forno E, Lescher R, Strunk R, Weiss S, Fuhlbrigge A, Celedón JC. Childhood Asthma Management Program Research Group. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol. 2011; 127: 741-749. CrossRef PubMed

[75] Quinto KB, Zaraw BL, Poon K-YT, Chen W, Schatz M, Christiansen SC. The association of obesity and asthma severity and control in children. J Allergy Clin Immunol. 2011; 128: 964-969. CrossRef PubMed

[76] Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008; 178: 682-687. CrossRef PubMed

[77] Boulet L-P, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007; 101: 2240-2247. CrossRef PubMed

[78] Camargo CA Jr, Boulet L-P, Sutherland ER, Busse WW, Vancey SW, Emmett AH, Ortega HG, Ferro TJ. Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. J Asthma. 2010; 47: 76-82. CrossRef PubMed

[79] Vom Hove M, Neinting MP, Bertsche T, Prenzel F. Biologicals in the treatment of pediatric atopic diseases. Handb Exp Pharmacol. 2020; 261: 131-151. CrossRef PubMed

[80] Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeier L, Khurana S, Knight S, McDonald VM, Morgan RL, Ortega VE, Riguas D, Subbarao P, Tonia T, Adcock IM, Bleeker ER, Brightling C, Boulet L-P, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020; 55: 1900588. CrossRef PubMed

[81] Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, Hakulinen A, Paolozi L, Wajdula J, Zang C, Nelson H, Raible D. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011; 37: 1352-1359. CrossRef PubMed

[82] Wennel SE, Barnes PJJ, Bleeker ER, Bouquet J, Busse W, Dahlen S-E, Holgate ST, Meyers DA, Rabé KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg B, Lo KH, Watt R, Barmanathan ES, Chanez P; T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009; 179: 549-558. CrossRef PubMed

[83] Kurawilla M, Patrawala M, Levy JM, Shih J, Lee FE. Association of antieosinophil therapy with decreased body mass index in patients with severe asthma: A preliminary retrospective analysis. Ann Allergy Asthma Immunol. 2019; 122: 649-650. CrossRef PubMed

[84] Forno E, Han Y-Y, Mazumdar RH, Celedón JC. Insulin resistance, metabolic syndrome, and lung function in US adolescents with and without asthma. J Allergy Clin Immunol. 2015; 136: 304-11. e8. CrossRef PubMed

[85] Cardet JC, Ash S, Kusa T, Camargo CA Jr, Israel E. Insulin resistance modifies the association between obesity and current asthma in adults. Eur Respir J. 2016; 48: 403-410. CrossRef PubMed

[86] Wu TD, Keet CA, Fawzy A, Segal JB, Brigham EP, McCormack MC; Association of Metformin Initi-
tion of metformin initiation and risk of asthma exacerbation. A claims-based cohort study. Ann Am Thorac Soc. 2019; 16: 1527-1533. CrossRef PubMed

[87] Porsbjerg CM, Sverrild A, Lloyd CM, Menzies-Gow AN, Bel EH. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020; 2000260. CrossRef PubMed

[88] Zhu T, Wu X-L, Zhang W, Xiao M. Glucagon like Peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-κB (NF-κB) signaling pathway in mice. Int J Mol Sci. 2015; 16: 20195-20211. CrossRef PubMed

[89] Chen YC, Dong GH, Lin KC, Lee YL. Gender difference of childhood overweight and obesity in predicting the risk of incident asthma: a systematic review and meta-analysis. Obes Rev. 2013; 14: 222-231. CrossRef PubMed

[90] Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, Chmiel JF, Steinbach SF, Calatrana A, Togias A, Thompson KM, Szefler SJ, Sorkness CA. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011; 364: 1005-1015. CrossRef PubMed